{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:50:03Z","timestamp":1770072603853,"version":"3.49.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The present study aimed to develop a prediction model for predicting developing debilities after optic neuritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The data for this research was obtained from the Optic Neuritis Treatment Trial (ONTT). The predictive model was built based on a Cox proportional hazards regression model. Model performance was assessed using Harrell\u2019s C-index for discrimination, calibration plots for calibration, and stratification of patients into low-risk and high-risk groups for utility evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 416 patients participated. Among them, 101 patients (24.3%) experienced disability, which was defined as achieving or surpassing a score of 3 on the expanded disability status scale. The median follow-up duration was 15.5\u2009years (interquartile range, 7.0 to 16.8). Two predictors in the final predictive model included the classification of multiple sclerosis at baseline and the condition of the optic disk in the affected eye at baseline. Upon incorporating these two factors into the model, the model\u2019s C-index stood at 0.71 (95% CI, 0.66\u20130.76, with an optimism of 0.005) with a favorable alignment with the calibration curve. By utilizing this model, the ONTT cohort can be categorized into two risk categories, each having distinct rates of disability development within a 15-year timeframe (high-risk group, 41% [95% CI, 31\u201349%] and low-risk group, 13% [95% CI, 8.4\u201317%]; log-rank <jats:italic>p<\/jats:italic>-value of &amp;lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This predictive model has the potential to assist physicians in identifying individuals at a heightened risk of experiencing disability following optic neuritis, enabling timely intervention and treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1326261","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:16:55Z","timestamp":1704691015000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of a predictive model for predicting disability after optic neuritis: a secondary analysis of the Optic Neuritis Treatment Trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Siqian","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruitong","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1102353","DOI":"10.3389\/fneur.2023.1102353","article-title":"The acute optic neuritis network (ACON): study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis","volume":"14","author":"Asseyer","year":"2023","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis\u2014a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","article-title":"Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial","volume":"115","year":"2008","journal-title":"Ophthalmology"},{"key":"ref4","first-page":"1017","article-title":"The National eye Institute visual function questionnaire: experience of the ONTT. Optic neuritis treatment trial","volume":"41","author":"Cole","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/bjo.70.12.918","article-title":"Estimation of visual function after optic neuritis: a comparison of clinical tests","volume":"70","author":"Sanders","year":"1986","journal-title":"Br J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0161-6420(87)33349-4","article-title":"Deficits in visual function after resolution of optic neuritis","volume":"94","author":"Fleishman","year":"1987","journal-title":"Ophthalmology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/acn3.674","article-title":"Retinal measurements predict 10-year disability in multiple sclerosis","volume":"6","author":"Rothman","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102653","DOI":"10.1016\/j.nicl.2021.102653","article-title":"Cortical fractal dimension predicts disability worsening in multiple sclerosis patients","volume":"30","author":"Roura","year":"2021","journal-title":"Neuroimage Clin"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10439-022-02930-3","article-title":"Comparison of machine learning methods using Spectralis OCT for diagnosis and disability progression prognosis in multiple sclerosis","volume":"50","author":"Montolio","year":"2022","journal-title":"Ann Biomed Eng"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15722","article-title":"The macular retinal ganglion cell layer as a biomarker for diagnosis and prognosis in multiple sclerosis: a deep learning approach","author":"Montolio","year":"2023","journal-title":"Acta Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"103357","DOI":"10.1016\/j.compbiomed.2019.103357","article-title":"A mathematical model to predict the evolution of retinal nerve fiber layer thinning in multiple sclerosis patients","volume":"111","author":"Montolio","year":"2019","journal-title":"Comput Biol Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1177\/13524585221097566","article-title":"Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis","volume":"28","author":"Berek","year":"2022","journal-title":"Mult Scler"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/biomedicines11020606","article-title":"Serum Neurofilaments and OCT metrics predict EDSS-plus score progression in early relapse-remitting multiple sclerosis","volume":"11","author":"Tiu","year":"2023","journal-title":"Biomedicine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/1352458520935724","article-title":"Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis","volume":"27","author":"Bsteh","year":"2021","journal-title":"Mult Scler"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0197-2456(93)90015-6","article-title":"Design, methods, and conduct of the optic neuritis treatment trial","volume":"14","author":"Cleary","year":"1993","journal-title":"Control Clin Trials"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","article-title":"The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The optic neuritis study group","volume":"329","author":"Beck","year":"1993","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"The clinical profile of optic neuritis. Experience of the optic neuritis treatment trial.","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1001\/archopht.1997.01100160715008","article-title":"Visual function 5 years after optic neuritis: experience of the optic neuritis treatment trial. Optic Neuritis Study Group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/WNO.0000000000001424","article-title":"Development of a prognostic model for predicting multiple sclerosis after optic neuritis: a secondary analysis of data from the optic neuritis treatment trial","volume":"42","author":"Luo","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"ref23","volume-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"2004"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"key":"ref25","volume-title":"R: A language and environment for statistical computing","year":"2021"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1474-4422(16)00068-5","article-title":"Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study","volume":"15","author":"Martinez-Lapiscina","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1212\/WNL.14.10.926","article-title":"Clinical studies of multiple sclerosis in Israel. 3. Clinical course and prognosis related to age at onset","volume":"14","author":"Leibowitz","year":"1964","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1600-0404.1970.tb05604.x","article-title":"Clinical factors associated with increased disability in multiple sclerosis","volume":"46","author":"Leibowitz","year":"1970","journal-title":"Acta Neurol Scand"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/brain\/114.2.1045","article-title":"The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome","volume":"114","author":"Weinshenker","year":"1991","journal-title":"Brain"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.7861\/clinmedicine.17-6-530","article-title":"Multiple sclerosis, a treatable disease","volume":"17","author":"Doshi","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMoa011341","article-title":"A longitudinal study of abnormalities on MRI and disability from multiple sclerosis","volume":"346","author":"Brex","year":"2002","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","article-title":"The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/brain\/103.2.281","article-title":"Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients","volume":"103","author":"Confavreux","year":"1980","journal-title":"Brain"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/archneur.65.6.727","article-title":"Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up","volume":"65","year":"2008","journal-title":"Arch Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/1352458507086666","article-title":"Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon","volume":"14","author":"Bosca","year":"2008","journal-title":"Mult Scler"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clineuro.2007.01.007","article-title":"The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis","volume":"109","author":"Motamed","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11882-023-01102-0","article-title":"Multiple sclerosis pathogenesis and updates in targeted therapeutic approaches","volume":"23","author":"Vasileiou","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e004073","DOI":"10.1136\/bmjopen-2013-004073","article-title":"UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model","volume":"4","author":"Palace","year":"2014","journal-title":"BMJ Open"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1212\/01.wnl.0000341935.41852.82","article-title":"Early MRI in optic neuritis: the risk for disability","volume":"72","author":"Swanton","year":"2009","journal-title":"Neurology"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis","volume":"131","author":"Fisniku","year":"2008","journal-title":"Brain"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/archneur.61.9.1386","article-title":"Neurologic impairment 10 years after optic neuritis","volume":"61","author":"Beck","year":"2004","journal-title":"Arch Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and Aquaporin-4-IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1326261\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T14:55:10Z","timestamp":1704898510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1326261\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":45,"alternative-id":["10.3389\/fneur.2023.1326261"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1326261","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1326261"}}